Orakl Oncology

Villejuif, France

Cancer Drug Discovery Drug Development Biotech

Orakl Oncology leverages tumor avatars that combine best-in-class biology with high-quality clinical and molecular data at scale. Our techbio platform enables oncology players to identify relevant targets and deliver better drugs, faster. As a spin-out from the Gustave Roussy Institute, the world's 3rd best cancer center, Orakl Oncology was co-founded by a team of seasoned experts with decades of international experience in cancer cell biology and engineering.

✓Source: HealthTech Alpha by Galen Growth

Shareable draft

Check out Orakl Oncology on @MedStartr Today #DrugDevelopment #DrugDiscovery #CancerOncology #Cancer #Biotech #MedMo #MedStartrVentures

https://www.medstartr.ai/s/ArgESbZKsUs

Get Involved in Orakl Oncology

🏢Is this your company? Claim This Profile

Join MedStartr to verify with your work email and edit this profile

Company Info

Founded: 2023
Website: www.orakl-oncology.com/

Disease Areas

Drug Development Drug Discovery Cancer & Oncology

Technologies

TechBioDrug Discovery PlatformTarget IdentificationHumanized Models

🌐Website

What do you think of Orakl Oncology?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.